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A B S T R A C T
Tuberculosis (TB) is a global epidemic with devastating consequences. Emerging evidence suggests that B-cells
have the ability to modulate the immune response and understanding these roles during Mycobacterium tu-
berculosis (M.tb) infection can help to find new strategies to treat TB. The immune system of individuals with
pulmonary TB form granulomas in the lung which controls the infection by inhibiting the M.tb growth and acts
as a physical barrier. Thereafter, surviving M.tb become dormant and in most cases the host’s immunity prevents
TB reactivation. B-cells execute several immunological functions and are regarded as protective regulators of
immune responses by antibody and cytokine production, as well as presenting antigen. Some of these B-cells, or
regulatory B-cells, have been shown to express death-inducing ligands, such as Fas ligand (FasL). This expression
and binding to the Fas receptor leads to apoptosis, a major immune regulation mechanism, in addition to the
ability to induce T-cell tolerance. Here, I discuss the relevance of B-cells, in particular their non-humoral
functions by addressing their regulatory properties during M.tb infection.
1. Introduction
The TB epidemic is a global crisis and has plagued humankind
throughout history (Daniel, 2006). Although the rate of TB incidence
declined by 1.5% from 2014 to 2015, the World Health Organisation
estimated 10.4 million new cases of TB globally in 2015, with only six
countries accounting for 60% for all new cases. These included India,
China, Indonesia, Nigeria, Pakistan and South Africa (WHO, 2016).
Mycobacterium tuberculosis (M.tb) is transmitted via contagious air-
borne droplets spread through the air. These droplets may be inhaled by
a new host into their respiratory tract. The mycobacteria then elicit an
immune response which are contained in the lungs by caseous granu-
lomas. Approximately 10% of all infected people will develop active TB,
roughly 50% in the first year and 50% at a later stage in their lifetime
(Davies, 2005). This percentage increases to about 10% per year in
immunocompromised individuals including those who are human im-
munodeficiency virus (HIV) positive (Davies, 2005). There are several
exogenous factors influencing the rate of M.tb infection following ex-
posure, these mainly include behavioural risk factors such as smoking,
alcohol abuse, indoor air pollution, and rate of social mixing. En-
dogenous risk factors mainly affect the rate of the progression of TB
from infection to active disease, these include circumstances which
alter the immune response (Fig. 1).
M.tb’s unique ability to remain dormant in the host poses a major
problem for the effective control of TB (Ehlers and Schaible, 2012). The
lack of medications that can eradicate latent TB infection (LTBI) leads
to the potential for reactivation to active TB when the host’s immune
system is compromised. This presents major difficulties in countries
with a high HIV prevalence. Additionally, vaccine development is based
on the concept of protection post-infection. However because M.tb ba-
cilli can lay dormant, a successful vaccine must have the ability to
produce an immune response greater than that activated by a natural
infection (Kaufmann, 2007). Approaches used to develop vaccines focus
predominately on T-cell immunity, yet with increasing evidence of B-
cells able to modulate the immune response, more emphasis on char-
acterising B-cells may be of significant value (Chan et al., 2014).
The process in which B-cells and humoral immunity regulate the
immune response to TB is still unclear, therefor understanding the roles
of B-cells during M.tb infection may assist the design of new strategies
to treat disease. In the following sections, the functions of B-cells,
regulatory B-cells (Breg), and their cytokines are discussed, along with
their roles with regards to M.tb infection.
2. Tuberculosis and B-cells
Immune cells are transported through the bloodstream to lymphoid
and peripheral tissues where they demonstrate their functions in re-
sponse to antigens. These cells are then recruited to and accumulate at
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the site of infection. Active recruitment and local expansion of specific
immune cells results in selective accumulation at the site of infection
(Brighenti and Andersson, 2012). The host immune system forms an
organised conglomeration of cells known as a granuloma in response to
M.tb infection. Granulomas are vital for the control of infection and
they function as a physical, as well as an immune barrier, to prevent the
spreading of the disease. They provide a micro-environment in which T-
cells and macrophages can inhibit the growth of the M.tb. The surviving
M.tb become dormant, unless the host immunity or the signals main-
taining the granuloma diminish, which may lead to a reactivation of TB
infection (Saunders and Britton, 2007). As result, the proper control of
TB is essential. This is completed by the immune cells within the
granuloma which activate macrophages to kill the mycobacteria and
balance anti-inflammatory signals to reduce tissue damage. The most
predominant lymphocyte populations include the memory CD4+ Th1
cells in the granuloma and CD8+ cytotoxic T-cells mainly found in the
outer lymphocytic mantel around the granuloma (Brighenti and
Andersson, 2012). Both these populations are the primary controllers of
M.tb infection in humans (du Plessis et al., 2016a, 2016b). The CD4+ T-
cells’ main function is cytokine production and immunity against my-
cobacteria by means of a Th1 response. CD8+ T-cells also provide im-
munity against TB, however are more significant later in TB infection,
produce IFN-γ and control the lysis of infected cells (Hernandez et al.,
2010). T-cells play a vital role in activating macrophages by releasing
IFN-γ and TNF (Phuah et al., 2012).
The full involvement of B-cells in the control of TB in humans is
unknown, however B-cell depletion has been shown to retard the pro-
gression of mainly T-cell-mediated autoimmune diseases in humans and
mice. These include type 1 diabetes and multiple sclerosis (Mariño
et al., 2011; Meinl et al., 2011). A lack of cellular immune control is
associated with an increased activation of humoral immune responses
in M.tb infection in humans (Rahman et al., 2015).
B-cells are a subtype of lymphocytes. Naïve B-cells have not been
presented with an antigen and can be divided into three groups: B-1 B-
cells (which is further divided into B-1a and B-1b), follicular B-cells and
marginal zone (MZ) B-cells. B-cells are divided based on their locations,
migration ability and if their activation is T-dependant or T-in-
dependent (Allman and Pillai, 2008). B-cells execute many im-
munological functions and have been regarded mainly as protective
regulators of immune responses. They produce cytokines, antibodies,
and have the potential to present antigen (Mauri and Bosma, 2012).
These important modulating functions affect the development of im-
mune cells, including T-cells, macrophages, neutrophils and dendritic
cells (Chan et al., 2014). B-1 cells produce low affinity antibodies and
are functionally part of the innate immune response. B-1a cells are
responsible for natural and autoantibody production, whereas B-1b
cells produce adaptive immune responses to T-cell independent anti-
gens (Yanaba et al., 2008). Follicular B-cells are mature B-cells that
recirculate in the blood and, with the help of T-cells, can develop into
antibody producing memory B-cells. They associate with follicular
dendritic cells in the B-cell follicles of the lymph nodes and spleen. MZ
B-cells produce antibodies responsible for protection against blood-
borne pathogens, are found in the marginal zone of the spleen, and
provide early protection during pathogen infections (Yanaba et al.,
2008).
When naïve B-cells are activated by an M.tb antigen, they develop
into activated plasma cells which have the ability to secrete TB-specific
antibodies and produce cytokines (Rao et al., 2015). These antibodies
regulate effector functions such as opsonisation of bacterial cells, an-
tibody-dependant cellular cytotoxicity and neutralisation of secreted
antigens, as seen in Fig. 2. B-cells are also effective antigen-presenting
cells that respond to singular antigens or whole pathogens. These B-
cells can then be presented to CD4+ T-cells. As a result, B-cells con-
tribute to the induction of CD4+ T-cells responses to TB and provide
early protection against infection (Abbas et al., 2014). B-cell antibodies
can also promote antibody-mediated phagocytosis in which they
Fig. 1. The risk factors for TB infection and disease.
Adapted from Davies (2005).
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modify macrophage behaviour (Phuah et al., 2012).
Granuloma-associated B-cells are present in clusters and keep in
close proximity with CXCR5+ T-cell subsets and TB-infected macro-
phages (Chan et al., 2014). There is a significant up-regulation of IL-10
and IL-21 in TB granulomas which may assist regulatory and humoral
immune responses at the site of infection and these B-cells may be in-
volved in this mediation (Rahman et al., 2015). In non-human primates,
granuloma B-cells express CXCR5+, may be positive for Ki-67 and have
upregulated HLA-DR expression (Phuah et al., 2012). These activated B-
cells, plasma cells and antibodies are found in high concentrations
within the granuloma and have similar characteristics to those of
germinal centres. Phuah et al. (2012) demonstrated that plasma cells,
within the granuloma produced mycobacteria-specific antibodies and
infected tissues, contained higher levels of TB-specific IgG. These
findings illustrate that B-cells are present and actively secreting anti-
bodies specific for M.tb antigens at the site of infection in non-human
primates (Phuah et al., 2012). Additionally, B-cells can be antigen-
presenting cells that can engulf antigens or whole M.tb bacilli and
present them to T-cells in the granuloma (Zhu et al., 2010). Collec-
tively, these findings illustrate that B-cells regulate host-pathogen in-
teractions at the site of infection and there may be a significant benefit
to further study these interactions in the granuloma as immune cells are
recruited to and accumulate there.
3. Non-humoral B-cells and their regulatory cytokines
Inflammation is an effective immune response that is controlled by
the release of cytokines and anti-inflammatory mediators (Rosser and
Mauri, 2015). Cytokines are important regulators for the development
of naïve CD4+ T-cells once presented with antigen (Zhu et al., 2010). It
is well known that CD4+ T-cells play a vital role in determining B-cell
responses, however the role of B-cells modulating T-cells is less well
characterised.
B-cells have the ability to produce pro- and anti-inflammatory cy-
tokines when stimulated whole organisms (such as M.tb) or Toll-like
receptor (TLR) antigens, these include TNF-α, IL-10, IL-1β, IL-17 and IL-
21 (du Plessis et al., 2016a, 2016b). This illustrates that B-cells respond
to stimulations in a non-humoral manner, with the subset plasma
(memory) B-cells (CD19+CD27+−CD138+) contributing the highest
production of cytokines. The IL-10 production is remarkably higher in
plasma (memory) B-cells (CD19+CD27+−CD138+) than in plasma B-
cells (CD19+CD138+) and the greatest cytokine-production was at-
tained by TLR4 and TLR9 based stimulations. BCG stimulation induced
IL-1β production the strongest (du Plessis et al., 2016a, 2016b)
Du Plessis et al. (2016a, 2016b) also illustrated that plasma
(memory) B-cells (CD19+CD27+−CD138+) drive IL-21 and TNF-α
production. IL-21, a major growth factor for naïve B-cells, is responsible
for the differentiation of naïve and memory B-cells into plasma cells,
and has the ability to induce the maturation of CD8+ T-cells (Good
et al., 2006). TNF-α has many functions and has a cytotoxic synergy
with human interferon. TNF-α is necessary for the formation as well as
the maintenance of granulomas. They may also effect chemokine pro-
duction and extend the lifetime of plasmablasts (Cassese et al., 2003).
IL-21, a T-cell-derived cytokine, is notably higher in TB lesions than
when compared to other tissues in the distal lung parenchyma. IL-21 is
a B-cell stimulatory cytokine that controls the function of germinal
centre B-cells and induces IgG-secreting plasma cells (Rahman et al.,
2015). A supporting study demonstrated that IL-21R-deficient mice
showed a significant inefficiency in IgG1 production after antigen
priming. This illustrated the crucial role of IL-21 in plasma B-cell dif-
ferentiation (Ozaki et al., 2002). Additionally, it was more recently
observed that the in vivo production of IL-10 is dependent on the
production of IL-21 (Yoshizaki et al., 2012). Thus, one may reason that
IL-10 is mainly produced by regulatory B-cells (Bregs) cells found in TB
lesions, despite the number of other cell types that could potentially
produce IL-10 (Rahman et al., 2015). IL-21 may assist the increase of
IgG-secreting B-cells and as a result, contributes to TB infection per-
sistance. This could be due to the result of an impaired cellular immune
response (Rahman et al., 2015). Furthermore, increased IL-21 levels
promote the suppression of perforin expression in T-cells and promote
viral replication in the spleen of mice infected with the Coxsackievirus
(Xie et al., 2011).
Inflammatory effector B-cell subsets may enhance the development
of Th1 responses by producing IL-12, IFN-γ and TNF-α. This results in
Fig. 2. A depiction of multiple mechanisms of antibody-mediated protection against TB.
Adapted from Chan et al. (2014).
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an immune response and an early control of the TB infection (Chan
et al., 2014). On the other hand, anti-inflammatory B-cells have the
ability to secrete IL-4, IL-33 and TGF-β, which disrupt the Th1 in-
flammatory response and reduce tissue damage (Zhang et al., 2012).
4. Regulatory B-cells
B-cells are broadly known to be positive regulators of the immune
response as they produce antigen-specific antibodies. But, Breg cells
have the ability to also negatively regulate the immune response by
producing regulatory cytokines, as well as by interacting directly with
T-cells (Yoshizaki et al., 2012). Shimamura et al. (1982) demonstrated
that injecting C57BL/6 mice with sheep erythrocytes resulted in the
production of suppressor B lymphocytes which subsequently induced
antigen-specific suppressor T lymphocytes (Shimamura et al., 1982a,
1982b). Wolf et al. (1996) later showed that mice deficient in B-cells
rarely recovered from experimental autoimmune encephalomyelitis
(EAE), whereas wild-type (WT) mice did. This illustrated that B-cells
have the immunomodulatory function of supressing the severity of the
inflammatory disease (Wolf et al., 1996).
IL-10 producing B-cells- functionally named, B10, in humans and
mice have an additional suppressive ability compared to other B-cells.
IL-10 is an immune regulatory cytokine that allows Breg cells to inhibit
tissue-specific inflammation (Mauri and Bosma, 2012). B10 cells
therefor have the capability to suppress T-cell functions such as the
differentiation of Th1 cells that produce IFN-γ and TNF-α, as well as
Th17 cells that produce IL-17 (Flores-Borja et al., 2013). B10 cells have
suppressive functions in healthy patients and stimulate the expansion of
FoxP3+ regulatory T-cells (Treg), whilst a loss of suppressive ability is
observed, including the ability to maintain FoxP3+ Treg cells, in pa-
tients with autoimmune disorders. This immune suppression is medi-
ated by IL-10 (Flores-Borja et al., 2013). Additionally, CD19-deficient
mice lack B10 regulatory cells, which leads to worsened disease
symptoms and exacerbated inflammation during contact sensitivity, as
well as in the EAE model for multiple sclerosis (Matsushita et al., 2008;
Yanaba et al., 2008).
Patients infected with M.tb have higher levels of
CD19+CD1d+CD5+ Breg cells in the peripheral blood which supresses
Th17 responses and inhibits the production of IL-22 (Zhang et al.,
2014). However, CD19+CD1d+CD5+ Breg cells are also found in per-
ipheral blood of healthy patients but with a lower inhibitory activity.
This suggests that this Breg subset plays a role in maintaining immune
tolerance, like Tregs, in healthy patients (Zhang et al., 2012). Zhang
et al. (2014) illustrated that individuals with cavitary TB had higher
levels of CD19+CD1d+CD5+ Breg cells compared to TB patients
without cavity. However, because cavitary TB is a severe form of the
disease, this may illustrate that CD19+CD1d+CD5+ Breg cells impair
protective immunity and result in a more severe disease (Zhang et al.,
2014). Similarly, they further observed that an increase of TB antigen-
specific IL-22 response during anti-TB treatment correlates with a de-
crease in CD19+CD1d+CD5+ Breg cells (Zhang et al., 2014).
In another study, the number of circulating CD19+CD27hiCD38hi
plasmablasts in the peripheral blood expressing cell-surface IgG was
notably higher in individuals with active TB compared to the healthy
individuals (Ashenafi et al., 2013). CD19+CD24hiCD38hi Breg subset
has been reported to regulate inflammation and autoimmunity in hu-
mans and mice (Yanaba et al., 2008; Iwata et al., 2011). Similarly, Breg
cells may enhance pulmonary infiltration of FoxP3+ Treg cells which
inhibit allergic inflammation in mice infected with helminth (Amu
et al., 2010). However, Breg cells have also been discovered to inhibit
macrophages from producing TNF-α (Iwata et al., 2011).
In contrast to the Iwata et al. (2011) who reported the suppressive
ability of Bregs depends on IL-10, another study illustrated that IL-10
plays no role in the Breg inhibition of T-cells (Zhang et al., 2012). This
was seen previously by Tretter et al. (2008), in which human CD25+
Breg cells exhibited suppressive activity independent of IL-10
production. Zhang et al. (2012) also observed that co-culture of CD4+
T-cells and CD19+ B-cells caused a reduction in IL-10 production. Si-
milarly, this was also observed in the murine model where B-cell-de-
ficient mice had an increased production of IL-10 than the WT mice
(Maglione et al., 2007). Zhang et al. (2012) further illustrated that B-
cells can suppress the actvity of CD4+ T-cells without the induction of
Tregs. Additionally, effective antituberculosis treatment was observed
to restore the Th1 response, reduce the amount of Breg cells in the
peripheral blood and enhance the production of IL-22, which is in
agreement with previous studies which report that IL-22 plays a role in
preventing the replication of intracellular M.tb (Zeng et al., 2011;
Zhang et al., 2014). This illustrates that low frequencies of Breg cells
may be insufficient to prevent inflated inflammatory responses in in-
dividuals with autoimmune diseases and that high Breg cell frequencies
may prevent antimicrobial effector responses necessary for TB control
(Rao et al., 2015).
Fas ligand (FasL) expression was mainly reported on activated NK
cells, T-cells, tumour cells and at sites of immune privilege, however
studies have shown that Breg cells can also express FasL, as well as
other death-inducing ligands (Hahne et al., 1996). Though the cyto-
kine-based regulatory functions of B-cells have come into view, the
expression of death-inducing ligands and their ability to control Th cell
reactions by B-cells have been overlooked. FasL, similarly to IL-10, is
highly expressed in the CD5+ B-cell population, illustrating that these
cells may have a specialised regulatory function (Yang et al., 2013).
FasL is a member of the tumour necrosis factor protein family and binds
to its receptor, Fas, which triggers apoptosis (Hahne et al., 1996).
Apoptosis, or activation-induced cell death, is a major mechanism of
immune regulation mediated by death-inducing ligands (Lundy, 2009).
FasL expression can be induced under many circumstances which are
summarised in Table 1 (below). In a recent study, van Rensburg et al.
(2016, 2016b) showed that successful TB treatment induces B-cells with
a regulatory phenotype, including the ability to express FasL. The study
illustrates that there is an increased FasL and IL5RA expression from B-
cells in individuals with TB compared to healthy controls. Similarly, the
expression of FasL and IL5RA increases during TB treatment. These
results suggest that higher FasL and IL5RA expression is associated with
a healthy individual and can be an indication of regression from active
TB to LTBI or health (van Rensburg et al., 2016a, 2016b).
Maglione et al. (2007) infected B-cell deficient mice with M.tb and
found this led to aggravated lung granuloma formation, as well as in-
creased T-cells and neutrophils when compared to WT mice. Re-
markably, this increased imflammatory response was not as a result of
the absence of IL-10 production, as IL-10 was upregulated in the in-
fected B-cell deficient mice (Maglione et al., 2007). Another study
proposed that B-cells produce IL-10 not at the local site of inflammation
but rather in the spleen (Yanaba et al., 2008). Still, the expression of
death ligands may be induced in B-cells after activation by M.tb (Kemp
et al., 2004).
Additionally, emerging data suggest that B-cells participate in the
control and prevention of many T-cell mediated diseases such as,
Table 1
Stimulators of FasL expression on B-cells, adapted from Lundy (2009).
Stimulators of FasL on B-cells References
Schistosome egg antigen Lundy and Boros (2002)
Lipopolysaccharide Hahne et al. (1996)
Trypanosoma cruzi infection Zuñiga et al. (2002)
HIV or SIV infection Samuelsson et al. (1997)
MuLV infection Rich et al. (2006)
Epstein-Barr virus infection Tanner and Alfieri (1999)
Phorbol myristate acetate-ionomycin Hahne et al. (1996)
Ligation of CD54 (Burkitt lymphoma) Kim et al. (2007)
B7-H4 ligation (EBV lines) Song et al. (2008)
Cockroach allergen Lundy et al. (2005)
Toxic mistletoe lectin Büssing et al. (1999)
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autoimmunity and airway inflammation. Some of these studies suggest
that the expression of FasL and cell death induced by B-cells could have
a central role in inducing and maintaining tolerance. Minagawa et al.
(2004) studied this role of FasL in transplantation mice models in which
H-Y, a male histocompatibility antigen, containing male skin grafts
were rejected by syngeneic female mice. Though, when the female mice
were injected with male spleen cells prior to the skin graft, it was ac-
cepted. The study further illustrated with the use of WT and FasL-de-
ficient, lupus-prone (lpr), female mice as well as, WT, lpr, and FasL-
deficient, gld, male mice that H-Y tolerance is regulated by FasL+
splenocytes (Minagawa et al., 2004). They then demonstrated that
purified splenic FasL+ B-cells were sufficient to induce tolerance and
acceptance of skin grafts, suggesting that naïve, splenic B-cells in mice
can induce T-cell tolerance. These results are similar to those found in
the schistosome mouse model conducted by Lundy and Boros (2002).
5. B-cells during latent and active Tuberculosis
There is a limited understanding to the role of B-cells in TB infection
as immunoglobulins derived from B-cells were not able to play a sig-
nificant role in infections with intracellular pathogens (Achkar et al.,
2015). However, recent studies, although conflicting, have shown
otherwise. In individuals with active TB, the rate of B-cells were de-
scribed as unchanged (Barcelos et al., 2006), increased (Wu et al.,
2009), or decreased (Corominas et al., 2004) compared to those of
healthy individuals. Additionally, individuals with LTBI were described
to have lower B-cell rates when compared to healthy individuals
(Corominas et al., 2004), whilst individuals post successful TB treat-
ment were described to have higher rates of B-cells (Barcelos et al.,
2006; Joosten et al., 2016).
In a murine model in which the mice were B-cell deficient and in-
fected with M.tb, the M.tb was reported to be more virulent and the
bacterial load was significantly higher than that of WT mice (Maglione
et al., 2007). Additionally, the pulmonary granuloma formation of these
mice were less severe and they had a delayed dissemination of bacteria.
This illustrates that B-cells are necessary for the mediation of granu-
loma formation (Bosio et al., 2000; Maglione et al., 2007). Furthermore,
these mice were then reconstituted with naïve B-cells and developed
pulmonary granulomas and dissemination patterns similar to those of
WT mice (Bosio et al., 2000).
In a B-cell-deficient cynomolgus macaque model of TB infection
during the acute phase, no difference in the overall disease profession,
pathology or clinical outcome was observed compared to WT models.
However, when analysing the individual granulomas, B-cell depletion
resulted in altered cytokine and T-cell responses, decreased levels of
inflammation and an increased bacterial load (Phuah et al., 2016).
Additionally, there were higher rates of T-cells producing IL-10, IL-17
and IL-2, whereas an overall lower rate of IL-10 and IL-6 in the gran-
ulomas. This could be attributed to the B-cell depletion (Phuah et al.,
2016). These findings illustrate that B-cells are able to regulate the
granuloma response to TB infection in macaques during acute infection.
During active TB disease, the production of several immuno-reg-
ulatory and inflammatory cytokines may affect the outcome of the
disease at the site of infection. Th1 (IFN-γ and TNF-α) and Th17 (IL-17)
cytokines control granuloma formation and stimulate the bactericidal
functions of T-cells and macrophages, whilst anti-inflammatory (IL-10
and TGF-β) and Th2 (IL-4 and IL-13) cytokines neutralise over ex-
aggerated Th1 responses and promote humoral responses (Rahman
et al., 2015).
Du Plessis et al. (2016a, 2016b) discovered distinctive B-cell var-
iations during active TB infection, other lung-based diseases, as well as
after treatment. Memory B-cell (CD19+IgM+CD138+CD27+) fre-
quencies were notably higher at diagnosis compared to post treatment
(6 months) in both class switched and non-class switched phenotypes.
Circulating MZ B-cells could differentiate between TB diagnosis and the
end of treatment, as well as when compared to other-lung based
diseases. These results warrant further research as potential biomarkers
for TB treatment (du Plessis et al., 2016a, 2016b).
Interestingly, during active TB, a decreased expression of mRNA of
B-cell associated genes was described and returned to normal again
following treatment. Additionally, between the time of diagnosis and
the completion of treatment, these genes were the most differentially
regulated (Cliff et al., 2013). In another study, IL-13 mRNA expression
was described 190–250 days prior to TB diagnosis in high risk in-
dividuals for TB infection (Sloot et al., 2015).
FASLG, IL-4, IL5RA, APRIL and CD38 expression were found to be at
lower levels in individuals with TB compared to healthy controls.
However, after 6 months, FASLG and IL5RA expression were increased
in individuals with TB again. This illustrates that the activity of B-cells
reduces during M.tb infection and is restored post successful TB treat-
ment and suggessts B-cells play a protective role in the immune system
against M.tb infection (van Rensburg et al., 2016a, 2016b).
Circulating B-cell frequencies are lower in individuals with active
TB. Additionally, B-cells obtained from individuals with both active
disease or LTBI are functionally impaired, yet found to be normal in
individuals post successful TB treatment (Joosten et al., 2016). These
impairments were more severe in individuals with active TB compared
to those with LTBI. However, within the LTBI group, considerable
variation was observed. This variation may be a reflection of the
spectral nature of LTBI (Lawn and Zumla, 2011). These findings suggest
that these impairments occur during active M.tb replication. Moreover,
the B-cell depletion notably influenced the T-cell populations which
supports the notion that B-cells are functionally involved in the acti-
vation of T-cells (Joosten et al., 2016). These findings cannot demon-
strate whether inherent defects in B-cells allow for the progression from
exposure to TB disease in the individuals or if the B-cell defect is at-
tained as a result of M.tb infection. Overall, this data demonstrates that
B-cells are functionally impaired during active TB which has significant
consequences for the activation of T-cells and could affect the outcome
of TB infection.
6. Conclusion
Although our knowledge of the role of B-cells and specifically Breg
cells during M.tb infection and TB disease is still limited, studies have
shown B-cells to play an active role in protection against M.tb. B-cell
mediated immune responses against M.tb in mice and non-human pri-
mates suggests a critical role of B-cells in the early stages of infection.
Additionally, the regulatory functions of B-cells and their association
with T-cells may play a vital role in determining the outcome of TB
infection in humans. Low levels of Breg cells may fail to prevent inflated
inflammatory responses, whilst high levels prevent antimicrobial ef-
fector responses required to control infections. From recent studies, we
deduce that FasL expression by B-cells is of significant value in viral,
bacterial and parasitic infections, as well as in immune-mediated dis-
eases. This expression by B-cells also plays a central role in the induc-
tion of T-cell tolerance, resulting in either a protective or pathogenic
role depending on the disease under question. In conclusion, further
characterising the role of B-cells, as well as regulatory B cells, during
M.tb infection and disease can aid in the discovery of new approaches to
the prevention and treatment of M.tb infection and TB disease.
7. Future applications
Lundy and Boros (2002) illustrated that splenic CD5+ B-cells ex-
press FasL and produce IL-10 at higher frequencies than splenic CD5−
B-cells. This, combined with studies illustrating increased T-cell acti-
vation in CD5+ B-cell-deficient mice, may suggest that these B-cell
populations can regulate T-cell activation (Lundy et al., 2005). It would
be interesting to study these cells further as they could potentially be a
target for producing cell-based, antigen-specific immunotherapy stra-
tegies by regulating T-cell mediated inflammation.
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Additionally, van Rensburg et al. (2016, 2016b) demonstrated that
IL5RA and FASLG were decreased in individuals with TB compared to
healthy controls, however these genes were upregulated again 6
months’ post treatment. This suggests that these genes may be used as a
bio-signature to observe the outcome of the treatment.
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